Drug intelligence / Profile preview

DB-1202

Development stage: Phase 2
Lead developer: Duality Biotherapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

DB-1202 is a novel antibody-drug conjugate (ADC) developed by Duality Biologics for the treatment of advanced solid malignant tumors. It is currently in phase 1/2 clinical trials to evaluate its tolerability, safety, pharmacokinetics, and antitumor activity in patients with advanced solid neoplasms. The specific mechanism of action and molecular target have not been disclosed publicly as of the latest updates.

Beyond the preview

Go deeper on DB-1202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DB-1202.

Explore the full profile